John Stagg
Impact in
- Physiology top 0.01%
- Adenosine and Purinergic Signaling
- Immunology top 0.2%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Immune cells in cancer
Papers in
- Physiology 56
- Adenosine and Purinergic Signaling 56
- Oncology 63
- Cancer Immunotherapy and Biomarkers 38
- Peptidase Inhibition and Analysis 25
- CAR-T cell therapy research 12
- Co-authors
- Mark J. SmythBertrand AllardSandra PommeyPhillip K. DarcyJacques GalipeauPaul A. BeavisDavid AllardUpulie Divisekera
In The Last Decade
John Stagg
108 papers receiving 11.0k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Physiology 4.1k
- Immunology 4.4k
- Oncology 5.0k
- Genetics 1.3k
- Biological Psychiatry 168
Countries citing papers authored by John Stagg
This map shows the geographic impact of John Stagg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Stagg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Stagg more than expected).
Fields of papers citing papers by John Stagg
This network shows the impact of papers produced by John Stagg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Stagg. The network helps show where John Stagg may publish in the future.
Co-authors
The 25 scholars most cited alongside John Stagg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 7 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 4 | |
| 5 | 2023 | 13 | |
| 6 | 2022 | 6 | |
| 7 | 2022 | 10 | |
| 8 | 2021 | 51 | |
| 9 | Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy Hit paper breakdown → | 2020 | 910 |
| 10 | 2018 | 5 | |
| 11 | 2017 | 259 | |
| 12 | 2016 | 142 | |
| 13 | 2016 | 26 | |
| 14 | 2015 | 270 | |
| 15 | 2015 | 162 | |
| 16 | 2015 | 207 | |
| 17 | 2013 | 372 | |
| 18 | 2012 | 174 | |
| 19 | 2011 | 320 | |
| 20 | 2007 | 39 |
About John Stagg
John Stagg is a scholar working on Physiology, Oncology, Immunology, Genetics and Biological Psychiatry, having authored 110 papers that have together received 11.1k indexed citations. Recurring topics across this work include Adenosine and Purinergic Signaling (56 papers), Cancer Immunotherapy and Biomarkers (38 papers), Peptidase Inhibition and Analysis (25 papers), Immune Cell Function and Interaction (23 papers), Immunotherapy and Immune Responses (20 papers), Nanoplatforms for cancer theranostics (13 papers), CAR-T cell therapy research (12 papers) and Mesenchymal stem cell research (8 papers). The work is most often cited by research in Physiology (4.1k citations), Immunology (4.4k citations), Oncology (5.0k citations), Genetics (1.3k citations) and Biological Psychiatry (168 citations). John Stagg has collaborated with scholars based in Canada, Australia and Belgium. Frequent co-authors include Mark J. Smyth, Bertrand Allard, Sandra Pommey, Phillip K. Darcy, Jacques Galipeau, Paul A. Beavis, David Allard, Upulie Divisekera, Sherene Loi and Simon C. Robson. Their work appears in journals such as Cancer Research, OncoImmunology, Proceedings of the National Academy of Sciences, The Journal of Immunology and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.